Champions TumorGrafts Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496
Identifying and developing targeted oncology compounds is often an arduous, costly and time-consuming process. As the demand for effective personalized oncology therapies grow, so does the need for a more predictive model solution.
Champions Oncology’s predictive patient-derived xenograft (PDX) models, Champions TumorGrafts, helps bridge the translational gap in oncology drug development by providing a highly-focused and accelerated simulated clinical trial.
The value of Champions TumorGrafts are demonstrated in our latest case study, which shows how the utilization of our PDX models in a screening and efficacy evaluation impacted the development of a novel compound, the dual BRAF-EGR inhibitor, CEP-32496.
To download the case study, please complete the form on the right.